U.S. Markets closed

3 Biotech Stocks That Soared This Week: Are They Buys?

Keith Speights, The Motley Fool

You know it's a good week when a stock in your portfolio soars 28%. Actually, good is probably an understatement. But that's exactly what three biotech stocks did this week. And two of them enjoyed much greater gains.

Juno Therapeutics (NASDAQ: JUNO), Jounce Therapeutics (NASDAQ: JNCE), and Sorrento Therapeutics (NASDAQ: SRNE) saw their stocks surge over the last few days. Here's why -- and whether or not any of these three hot biotech stocks are smart picks for investors right now. 

Businessman with wings drawn over him next to line chart pointing up

Image source: Getty Images.

Juno Therapeutics

Juno Therapeutics was the biggest winner of the week, with its stock skyrocketing nearly 40%. The reason behind this huge jump can be explained in one word: Celgene (NASDAQ: CELG).

On Tuesday, The Wall Street Journal reported that Celgene was in talks to buy Juno. Only nine days earlier, the big biotech announced plans to buy privately held Impact Biomedicines for $1.1 billion upfront and up to $7 billion with milestone payments.

Celgene and Juno began a partnership in 2015 to develop cell therapies focusing particularly on chimeric antigen receptor T cell (CAR-T) drugs, with Celgene buying a 10% stake in the smaller company. Juno is one of a handful of small biotechs with expertise in cell therapy, which made it an attractive acquisition target after Gilead Sciences bought Kite Pharma last year. 

Jounce Therapeutics

Another Celgene partner, Jounce Therapeutics, was also a big mover. Jounce stock gained over 32% this week and is up more than 60% so far in 2018.

What made Jounce bounce? Speculation that the small biotech might be next on Celgene's target list. Celgene already owns a small stake in Jounce after the two companies initiated a collaboration in 2016 to develop immuno-oncology drugs.

Jounce's lead candidate is JTX-2011, which activates the inducible T cell co-stimulator (ICOS) protein found on the surface of some T cells. Activation of the ICOS protein is believed to cause the body's immune system to fight cancer cells. Jounce is evaluating JTX-2011 in a phase 2 study targeting treatment of multiple solid tumors.

Sorrento Therapeutics

Sorrento Therapeutics stock jumped 28% this week. Is the biotech yet another acquisition candidate for Celgene? Probably not -- but it just might be for another big biopharmaceutical company down the road.

Sorrento has its own CAR-T research program, but is taking a different approach with its CD38 CAR-T candidate. The biotech uses a non-viral method to generate CAR-T cells. Sorrento thinks this approach should be quicker to develop than using CAR gene-encoding lentivirus, retrovirus, or adeno-associated virus (AAV), and could eliminate the need for a lengthy monitoring period of patients after treatment.   

The big jump for Sorrento stock this week likely stems from two things. First, H.C. Wainwright analyst Raghuram Selvaraju raised his price target for the stock from $20 to $30. Selvaraju's outlook is more positive for the biotech, in part because of the potential for approval of lead candidate ZTlido in treating pain associated with postherpetic neuralgia. Second, Sorrento probably received a higher level of interest after news broke about Celgene's potential acquisition of Juno.

Are they buys?

Are any of these high-flying biotech stocks good choices for investors after their big runs? With Juno, it depends on whether or not the reports about the Celgene acquisition are true, and if they are, how much the big biotech is willing to pay.

My hunch is that the reports indeed are true. I can see why Celgene would want to buy Juno outright instead of only partner with the small biotech. As for the price tag, some think Celgene would pay up to $12 billion -- close to what Gilead shelled out for Kite. I don't think the price will be that high, but I could be wrong. My view is that Juno could still go higher, but to buy the stock now would be more speculation than investing.

Even after its nice gain, Jounce Therapeutics' market cap is around $700 million. If the company is successful with JTX-2011, Jounce should be worth a lot more. However, there's no way to know if the biotech's phase 2 results will be positive. Buying the stock could pay off in a huge way -- but it could also backfire.

Sorrento is the closest to having an approved product of the three, with the FDA scheduled to make a decision on approval for ZTlido by Feb. 28, 2018. There's a possibility that ZTlido could take a significant market share away from generic Lidoderm. And Sorrento's non-viral CAR-T program is intriguing. For now, however, I think Sorrento is still a stock to watch closely rather than buy.

More From The Motley Fool

Keith Speights owns shares of Celgene and Gilead Sciences. The Motley Fool owns shares of and recommends Celgene and Gilead Sciences. The Motley Fool recommends Juno Therapeutics. The Motley Fool has a disclosure policy.

  • Corning's Growth Accelerates as Investments Begin to Pay Off
    Business
    Motley Fool

    Corning's Growth Accelerates as Investments Begin to Pay Off

    Corning Incorporated (NYSE: GLW) announced better-than-expected third-quarter 2018 results early Tuesday, highlighting broad growth from each of its various business segments, improving margins, and an increased full-year outlook. Let's take a closer look at what drove Corning's latest quarterly beat, and what investors should be watching as we look ahead. On Corning's consolidated results, core sales grew 15.6% year over year to $3.05 billion, translating to 18% growth in core earnings to $476 million.

  • Mega Millions $1.6 Billion Jackpot Also Comes With a Mega Millions Tax Bill
    Finance
    Fortune

    Mega Millions $1.6 Billion Jackpot Also Comes With a Mega Millions Tax Bill

    With a jackpot of $1.6 billion, tonight’s Mega Millions lottery drawing is the biggest in history. The Mega Millions drawing will be held Tuesday night at 11 p.m. ET—and the odds are categorically against you. The Mega Millions tax bite, though, is pretty solid.

  • Activision Blizzard (ATVI) Dips More Than Broader Markets: What You Should Know
    Finance
    Zacks

    Activision Blizzard (ATVI) Dips More Than Broader Markets: What You Should Know

    In that same time, the Consumer Discretionary sector lost 6.58%, while the S&P 500 lost 5.71%. ATVI's full-year Zacks Consensus Estimates are calling for earnings of $2.65 per share and revenue of $7.50 billion. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

  • Companies Say They're Ready to Move Supply Chains From China
    News
    Bloomberg

    Companies Say They're Ready to Move Supply Chains From China

    A common theme is that they are ready to relocate supply chains if the cost of importing Chinese goods becomes prohibitive. "If there was a broad-based tariff on apparel, I think you could see a bit more of an acceleration of the migration out of China into other regions for apparel sourcing," Mitch Butier, chief executive officer of the California label producer, said during an Oct. 23 earnings call. A number of them have already moved out of China," Jean-Jacques Ruest, CEO of the Canadian railway company said during an Oct. 23 earnings call.

  • 2 More Marijuana Stocks Are Moving to the NYSE
    Business
    Motley Fool

    2 More Marijuana Stocks Are Moving to the NYSE

    This year, we've witnessed GW Pharmaceuticals gain approval in the U.S. for the first cannabis-derived drug, and we watched as Vermont legalized recreational marijuana use entirely through the legislative process. This began with Cronos Group at the end of February, when it chose to list its shares on the Nasdaq. It was followed just a few months later by Canopy Growth Corp., which became the first marijuana stock to list on the NYSE.

  • News
    CNBC

    Here's how much money you should have saved by 50

    Fidelity, the nation's largest retirement-plan provider, recommends having the equivalent of six times your annual salary saved. To get to that number, Fidelity recommends saving 15 percent of your annual income. Make sure to invest these funds instead of leaving them in a traditional low-interest savings account.

  • The stock market's 'dead cat bounce' is over and the rolling bear market is making a comeback, Morgan Stanley says
    Business
    Business Insider

    The stock market's 'dead cat bounce' is over and the rolling bear market is making a comeback, Morgan Stanley says

    The stock market may have bounced back from its sharp sell-off at the beginning of October, but Morgan Stanley says the selling will pick back up soon. The firm expects the S&P 500 to slide back below the 200-day moving average, a key technical level. Tread carefully in tech and consumer discretionary, Morgan Stanley warns.

  • Why Investors Are Paying a Premium for These 3 Biotech Stocks
    Business
    Motley Fool

    Why Investors Are Paying a Premium for These 3 Biotech Stocks

    Amarin stock exploded in September because it looks like Vascepa will become the next go-to drug for this enormous population. During the 8,179-patient Reduce-It trial, patients given Vascepa in addition to their normal statin treatments were 25% less likely to suffer a major cardiovascular event such as a heart attack. Over the past year, Amarin Corporation actually lost $92 million because sales of Vascepa just haven't kept pace with operating expenses.

  • 5 Deeply Discounted Value Stocks That Haven't Been This Cheap in at Least a Decade
    Business
    Motley Fool

    5 Deeply Discounted Value Stocks That Haven't Been This Cheap in at Least a Decade

    October has been a wake-up call for investors that the stock market won't go up in a straight line, even if we'd like it to. Sure, Bank of America (NYSE: BAC) has seen its stock catapult higher from its Great Recession lows, but its forward P/E of 9.8 would represent a more-than-decade low for the stock.

  • MARKETS: Here's why stocks are selling off right now and what a bottom would look like
    Business
    Yahoo Finance Video

    MARKETS: Here's why stocks are selling off right now and what a bottom would look like

    Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Seana Smith to discuss the latest market moves.

  • Why Tesla Stock Jumped Tuesday
    Business
    Motley Fool

    Why Tesla Stock Jumped Tuesday

    Shares of electric-car company Tesla (NASDAQ: TSLA) popped on Tuesday, rising as much as 7.5%. The stock's rise comes after the electric-car company scheduled its earnings report about a week earlier than usual with just two days' notice, leading to some speculation that the automaker may have achieved its goal to become profitable during the quarter. Citron Research, which had previously encouraged investors to short Tesla stock, is now reversing its stance on the stock.

  • Trump’s Tax Push to Help Middle Class Could Help Top Earners Too
    Politics
    Bloomberg

    Trump’s Tax Push to Help Middle Class Could Help Top Earners Too

    It’s still unclear how Trump will propose to reduce the tax burden on middle-class Americans, but one of the most straightforward ways would be to lower rates by 10 percent for single filers making up to $82,500. U.S. income tax rates are graduated and income dollars get taxed in chunks as they move up through the brackets -- which means wealthy Americans would also get to apply the reduced rate on their first dollars of income. “A millionaire gets the same size tax cut,” said Kyle Pomerleau, an economist at the conservative Tax Foundation.

  • Suze Orman missed the point of retirement, and that’s why she went back to work
    News
    MarketWatch

    Suze Orman missed the point of retirement, and that’s why she went back to work

    Suze Orman did a smackdown of the FIRE (Financial Independence/Retire Early) movement on Paula Pant’s podcast. Coach Carson posted a balanced, informative response, appreciating Suze’s admonition to be sure you have enough for a risk-free retirement. Suze enumerated a string “what can go wrong” scenarios as evidence that early retirement (on less than $10 million) leaves you vulnerable when life hands you lemons — a whole tree of lemons.

  • These stocks may be sacrificed in a cold war with China
    COL
    CNBC Videos

    These stocks may be sacrificed in a cold war with China

    Jim Cramer says the escalation in the United States' trade war with China could end in an outright cold war that debilitates parts of the stock market.

  • Banks vs. Big Tech: 4 to Buy, 4 to Sell
    Finance
    InvestorPlace

    Banks vs. Big Tech: 4 to Buy, 4 to Sell

    Investors on Wall Street continue to contend with a choppy and uncertain trading environment, even among popular sectors like tech stocks. A growing chorus on Wall Street is sounding the alarm, with analysts at Morgan Stanley warning that the large-cap stocks in the S&P 500 are the only holdout from a “rolling bear market’ that has already savaged pretty much every other asset class, including small-cap stocks, high-yield bonds, and emerging market assets. The fact that the S&P 500 is once again below its 200-day moving average supports this thesis, weighed down by bank stocks.

  • Why These 3 Top Marijuana Stocks Slumped Today
    Business
    Motley Fool

    Why These 3 Top Marijuana Stocks Slumped Today

    With earnings season hitting a crescendo this week, investors are looking closely at the specific prospects for certain corners of the market, and that's contributing to disparities among the various major benchmarks followed most often by investors. Amid the crosscurrents, marijuana stocks took particularly hard hits, and New Age Beverages (NASDAQ: NBEV), Tilray (NASDAQ: TLRY), and Canopy Growth (NYSE: CGC) were among the worst performers on the day. All three of these stocks have given back some of their gains following the long-awaited legalization of recreational cannabis in the Canadian market last week. In the month leading up to the Oct. 17 start date for legal cannabis sales, New Age Beverages tripled in value, while Tilray had more than doubled since the end of August, and Canopy Growth had seen more modest gains of between 10% and 20%.

  • The $1.6B Lottery Jackpot Is Still Up for Grabs — but the Tax Bill for the Winner Will Be Massive
    Finance
    GoBankingRates

    The $1.6B Lottery Jackpot Is Still Up for Grabs — but the Tax Bill for the Winner Will Be Massive

    Whoever wins the Mega Millions lottery could face over 40 percent in taxes. Lines are growing at convenience stores and gas stations as the Mega Millions lottery grows to its biggest prize ever. The cash option is $904 million, which gives you a lot of options of how to spend it until you take taxes into consideration.

  • Tesla Skeptic Andrew Left Is Now Long on ‘Proven Hit’ Model 3
    Business
    Bloomberg

    Tesla Skeptic Andrew Left Is Now Long on ‘Proven Hit’ Model 3

    Citron Research’s Andrew Left, a vocal and long-term Tesla short, said in a report Tuesday that the electric-car maker is snatching customers from BMW, Mercedes, Toyota and Honda. In a Bloomberg Television interview, he said Chief Executive Officer Elon Musk has distracted investors from a company that’s turning a corner. “Elon Musk has made such a sideshow of himself that people started to forget about -- including myself -- the underlying business,” Left said on Bloomberg TV.

  • Finance
    CNBC

    The fear gauge and strong earnings tell Jim Cramer this bottom in the stock market may be real

    The Cboe Volatility Index and strong earnings reports from key companies helped stocks recover intraday on Tuesday, CNBC's Jim Cramer says. The Cboe Volatility Index , also known as the stock market's fear gauge or the VIX, flashed a signal that could mean the market bottomed during Tuesday's turbulent trading session , CNBC's Jim Cramer said. Last week, the "Mad Money" host called on technician Mark Sebastian, who specializes in volatility, to get a read on the VIX , which measures expectations of near-term volatility by tracking S&P 500 option prices.

  • Why Nektar Therapeutics Crashed 17.2% Today
    Business
    Motley Fool

    Why Nektar Therapeutics Crashed 17.2% Today

    After delivering a disappointing update on NKTR-214 in cancer patients this summer, Nektar Therapeutics' (NASDAQ: NKTR) shares have been struggling. The company didn't report any news today, so a negative report issued by Plainview LLC this month may be to blamed for its 17.2% tumble today. In February, Bristol-Myers Squibb (NYSE: BMY) inked a blockbuster deal to license rights to NKTR-214 following positive data last year for NKTR-214's use alongside Bristol-Myers' Opdivo.

  • 4 Things Aurora Cannabis Did Right Before Its NYSE Debut
    Business
    Motley Fool

    4 Things Aurora Cannabis Did Right Before Its NYSE Debut

    Aurora Cannabis (NASDAQOTH: ACBFF) (TSX: ACB) has sought to make it even easier for U.S. investors to buy its shares by arranging to have its shares listed on the New York Stock Exchange. Beginning tomorrow, Oct. 23, Aurora will join the elite group of cannabis companies whose shares trade on major U.S. exchanges. Getting ready for the increased exposure that a NYSE listing brings takes time and effort, and Aurora Cannabis hasn't wasted any time.

  • S&P 500 closes down for fifth day as stocks retreat in wake of China selloff
    News
    MarketWatch

    S&P 500 closes down for fifth day as stocks retreat in wake of China selloff

    U.S. stocks bounced off intraday lows and major indexes trimmed early losses Tuesday, but the S&P 500 still finished lower for a fifth session as a big drop in the Chinese market revived fresh questions about the global economy. The Dow Jones Industrial Average (DJIA) fell 125.98, or 0.5%, to 25,191.43 after being down more than 500 points earlier. (DJIA)On Monday, Dow industrials and the S&P 500 closed lower while the Nasdaq bucked the trend to edge higher.

  • Finance
    CNBC

    Here's the tax bite on $1.6 billion Mega Millions and $620 million Powerball jackpots

    Strategies can be employed to reduce the amount of your win that is taxed, although they are best explored with the help of an experienced tax advisor. While it's anyone's guess who will end up winning the Mega Millions and Powerball jackpots, there's at least one guaranteed recipient of a chunk of the loot — the IRS. With the Mega Millions jackpot at $1.6 billion and Powerball's top prize at $620 million, that tax bill will be hefty even if the winner employs strategies to reduce their taxable income.

  • One of the largest cannabis companies is going public on the New York Stock Exchange
    Business
    Business Insider

    One of the largest cannabis companies is going public on the New York Stock Exchange

    Aurora Cannabis, one of the largest Canadian marijuana producers, is going public on the New York Stock Exchange. Aurora is joining a select list of Canadian cannabis producers, including Tilray and Cronos, that are able to list on US-based exchanges.

  • Watch out for ‘dead cat bounce’ in stocks because there’s more pain ahead: Morgan Stanley’s Wilson
    News
    MarketWatch

    Watch out for ‘dead cat bounce’ in stocks because there’s more pain ahead: Morgan Stanley’s Wilson

    October is living up to its infamous reputation as a volatile month for stocks with major indexes down sharply and there is likely more pain ahead for investors, according to one prominent Wall Street analyst. The recent rebound “was a dead cat bounce,” said Michael Wilson, an equity strategist at Morgan Stanley, in a report. After eking out gains last week, the S&P 500 (SPX) is trading below the 200 DMA of 2,768 thus far this week as stocks remain under pressure with third-quarter earnings cycle picking up pace.